What is it about?
Cancer treatment have undergone a huge development during last decades, with improved survival and access to new treatments. Cancer treatment and acute care near end-of-life, are indicators of quality of care. This paper explores aggressiveness of care at end-of-life in two cohorts with lung or pancreatic cancers.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
It is important to be precise in juding when to not start or when to stop potentially toxic cancer treatments, and give time for preparations at end-of-life.
Perspectives
We face challenges in cancer care, and this includes precision in assessment of prognosis and clarity of goals of care.
Helena Ullgren
Karolinska Institutet
Read the Original
This page is a summary of: Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts, PLoS ONE, July 2021, PLOS,
DOI: 10.1371/journal.pone.0254673.
You can read the full text:
Contributors
The following have contributed to this page
